Notification of Managers’ transactions
Company announcement no. 33 - 20 14 September 2020
Go here to see the original:
Notification of Managers’ transactions
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer
CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Michelle Quinn Smith as Chief Human Resources Officer. Ms. Smith brings over 30 years of experience in human resources to Voyager, including leadership roles at Flagship Pioneering, Takeda Pharmaceuticals, Genzyme, and Sanofi.
See original here:
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer
PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
SPARTA, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit as follows:
The rest is here:
PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment
LYON, France and CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the hosting of a Key Opinion Leader (KOL) Event to discuss the medical need in pancreatic cancer and the potential role of eryaspase in this setting.
Read more here:
ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment
Cronos Group Inc. to Present at the CIBC 19th Annual Eastern Institutional Investor Conference
TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, will speak at the CIBC 19th Annual Eastern Institutional Investor Conference on Thursday, September 17, 2020 at 2:40 p.m. EDT.
Link:
Cronos Group Inc. to Present at the CIBC 19th Annual Eastern Institutional Investor Conference
Biosenta Announces Royalty License Agreement for North American Distribution
TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Biosenta Inc. ("Biosenta" or the "Company") listed on the CSE (CSE:ZRO) is pleased to announce - A strategic licensing partnership with Kleen Bee Labs was finalized today. This license will give the rights for distribution of DualXtiv, a broad-spectrum anti-microbial disinfectant, to club level, mass grocery, and retail chains across North America.
See more here:
Biosenta Announces Royalty License Agreement for North American Distribution
Dyne Therapeutics Announces Closing of Initial Public Offering
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the closing of its initial public offering of 14,089,314 shares of its common stock at an initial public offering price of $19.00 per share, including 1,837,736 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Dyne. The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Dyne, were approximately $268 million.
See the original post:
Dyne Therapeutics Announces Closing of Initial Public Offering
ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen
LYON, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances in red blood cells (the "Company"), today announced the implementation of an at-the-market program allowing the Company to issue and sell ordinary shares in the form of American Depositary Shares ("ADSs"), to eligible investors at market prices, with aggregate gross sales proceeds of up to $30,000,000 (subject to a regulatory limit of 20% dilution), from time to time, pursuant to the terms of a sales agreement with Cowen acting as sales agent.
Read the original here:
ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020
Conference call and webcast on Tuesday, September 22 at 2:30 pm CET/8:30 am ET Conference call and webcast on Tuesday, September 22 at 2:30 pm CET/8:30 am ET
Here is the original post:
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020